ClinicalTrials.gg
TerminatedNCT03818672Updated Nov 30, 2023Results posted

Steady-State Pharmacokinetics of Rifaximin 550 mg Tablets in Healthy and Hepatically Impaired Subjects

A Phase 4 interventional study of Rifaximin in Severe Hepatic Impairment, sponsored by Bausch Health Americas, Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-11-30.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 4, Interventional, and Treatment

Why this study was terminated
Study determined to be infeasible.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
5
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary objective of this study is to characterize the steady state plasma

Read the detailed description

The primary objective of this study is to characterize the steady state plasma PK of rifaximin (550 mg BID) in subjects with severe hepatic impairment (MELD 19 to 25 and MELD >25), as well as healthy subjects with normal hepatic function.

02

Conditions studied

  • Severe Hepatic Impairment
03

In context

Lead sponsor

Bausch Health Americas, Inc. is the lead sponsor of 213 studies on the registry; 7 are open to participants now.

Of its 25 completed or terminated interventional studies of FDA-regulated products, 18 (72%) have results posted.

First submitted after Bausch Health Americas, Inc. became part of Bausch Health Companies Inc..

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hepatically impaired subjects will be ≥18 years of age, have a diagnosis of liver cirrhosis and a MELD score of ≥19 at Screening. Note: At least 6 of the hepatically impaired subjects will have a MELD score of >25.

Exclusion criteria

Exclusion Criteria:

  • Subject has known allergy to rifaximin, rifampin, or other rifamycins, and/or vehicles used in the formulation, or any other allergies.
  • Subject has participated in an drug or device study within 30 days prior to Day 1 (Baseline).
  • Subject has any concurrent illness (other than liver cirrhosis), disability or circumstance that may affect the interpretation of clinical data, could cause noncompliance with treatment or visits or otherwise contraindicates participation in this study in the opinion of the investigator.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Rifaximin

    Rifaximin 550 mg BID

    Drug: Rifaximin

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum Observed Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax) of rifaximin and 25-desacetyl rifaximin, if measurable

    Time frame: 7 days

  2. Time of the Maximum Concentration (Tmax)

    Time of the maximum concentration (Tmax) of rifaximin and 25-desacetyl rifaximin, if measurable

    Time frame: 7 days

  3. Area Under the Plasma Concentration Versus Time Curve (AUC) During the 12-hour Dose Interval

    Area under the plasma concentration versus time curve (AUC) during the 12-hour dose interval of rifaximin and 25-desacetyl rifaximin, if measurable

    Time frame: 7 days

07

Results

Posted Nov 30, 2023

Participant flow

Participant flow — Overall Study
MilestoneRifaximin
Started5
Completed5
Not completed0

Outcome measures

PrimaryMaximum Observed Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax) of rifaximin and 25-desacetyl rifaximin, if measurable

Time frame:
7 days
Reported as:
Geometric mean · ng/mL
Maximum Observed Plasma Concentration (Cmax)
ng/mLRifaximin
rifaximin13.4 ± 90.0
25-desacetyl rifaximin0.356 ± 87.5
PrimaryTime of the Maximum Concentration (Tmax)

Time of the maximum concentration (Tmax) of rifaximin and 25-desacetyl rifaximin, if measurable

Time frame:
7 days
Reported as:
Mean · hours
Time of the Maximum Concentration (Tmax)
hoursRifaximin
rifaximin0.688 ± 0.688
25-desacetyl rifaximin0.625 ± 0.750
PrimaryArea Under the Plasma Concentration Versus Time Curve (AUC) During the 12-hour Dose Interval

Area under the plasma concentration versus time curve (AUC) during the 12-hour dose interval of rifaximin and 25-desacetyl rifaximin, if measurable

Time frame:
7 days
Reported as:
Geometric mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUC) During the 12-hour Dose Interval
h*ng/mLRifaximin
rifaximin98.7 ± 107
25-desacetyl rifaximin3.04 ± 85.2

Adverse events

Collected over 7 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rifaximin0/5 (0%)0/5 (0%)2/5 (40%)
Most frequent other events
Most frequent other events
EventRifaximin
VomitingGastrointestinal disorders1/5
Tooth fractureInjury, poisoning and procedural complications1/5

Baseline characteristics

Age, Continuous
Age, Continuous(years)Rifaximin
Mean45.8 ± 6.870
Sex: Female, Male
Sex: Female, Male(Participants)Rifaximin
Female3
Male2
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Rifaximin
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White5
More than one race0
Unknown or Not Reported0
Model for End Stage Liver Disease Score at baseline: Healthy
Model for End Stage Liver Disease Score at baseline: Healthy(Participants)Rifaximin
Count of participants1
Model for End Stage Liver Disease Score at baseline: 19 to 25
Model for End Stage Liver Disease Score at baseline: 19 to 25(Participants)Rifaximin
Count of participants4
08

Study locations

1 site
  • Valeant Site 01
    San Antonio, Texas 78215, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in Feb 2020, 12 months.

Results were first posted in Nov 2023, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 22, 2019
First posted
Jan 28, 2019
StartActual
Jan 29, 2019
Primary completionActual
Feb 2, 2020
CompletionActual
Feb 2, 2020
Results first posted
Nov 30, 2023
Last update
Nov 30, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 30, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03818672
Responsible party
Sponsor
First posted
Jan 28, 2019
Start date
Jan 29, 2019
Primary completion
Feb 2, 2020
Completion
Feb 2, 2020
Results posted
Nov 30, 2023
Last update
Nov 30, 2023

Study contacts

Varsha Bhatt
study director · Bausch Health Companies

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rifaximin

Start the discussion